AJ Lanigan: Of Course. In actual fact, pharma firms are building big money with solutions like Keytruda and Opdivo that deal with PD-1 and PD-L1. Here’s the super amazing section: think about checkpoints as targeted traffic alerts. You don’t want an immune process that’s running wild similar to a freight waiting for link from Social Bookmarking (3)